Locoregional Treatment of Glioblastoma With Targeted α Therapy

医学 多塔 总体生存率 内科学 胶质母细胞瘤 不利影响 肿瘤科 核医学 癌症研究 体内 生物 生物技术
作者
Leszek Królicki,Jolanta Kunikowska,Frank Bruchertseifer,Radosław Kuliński,Dariusz Pawlak,Henryk Koziara,Rafał Rola,Alfred Morgenstern,Adrian Merlo
出处
期刊:Clinical Nuclear Medicine [Lippincott Williams & Wilkins]
卷期号:48 (5): 387-392 被引量:10
标识
DOI:10.1097/rlu.0000000000004608
摘要

Glioblastoma (GB) is the most malignant primary brain tumor. Therefore, introduction of new treatment options is critically important. The aim of this study was to assess local treatment with α emitters [ 213 Bi]Bi-DOTA-substance P (SP) and [ 225 Ac]Ac-DOTA-SP.Treatment was performed as salvage therapy in patients with recurrent primary and secondary GB. [ 213 Bi]Bi-DOTA-SP with injected activity 1.85 GBq per cycle was used in 20 primary (48.2 ± 11.8 years old) and in 9 secondary (38.8 ± 10.8 years old) GB patients and [ 225 Ac]Ac-DOTA-SP in 15 primary (45.1 ± 9.9 years old) and in 6 secondary (37.8 ± 6.4 years old) GB patients with a dose escalation scheme (10, 20, and 30 MBq).Local treatment with [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP was well tolerated with only few adverse effects. There was no statistically significant difference between [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP groups in survival parameters. For primary GB, survival parameters of patients treated with [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP were as follows(in months): progression-free survival time, 2.7 versus 2.4; OS-d (overall survival from time of diagnosis to death from any cause), 23.6 versus 21.0; OS-t (overall survival from the start of treatment to death from any cause), 7.5 versus 5.0; and OS-r (overall survival from recurrence in primary tumors to death from any cause), 10.9 versus 12.0. Survival parameters of secondary GB patients treated with [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP were as follows (in months): progression-free survival time, 5.8 versus 2.4; OS-d, 52.3 versus 65.0; OS-t, 16.4 versus 16.0; and OS-c (overall survival from conversion into secondary GB multiforme to death from any cause), 18.4 versus 36.0.The similarity results of 213 Bi or 225 Ac may suggest that the local treatment of brain tumors can be greatly simplified. The experience to date shows that local radioisotope treatment of brain tumors requires further dosimetry studies, taking into account the complexity of biological processes.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
可可完成签到,获得积分10
1秒前
sxp1031发布了新的文献求助10
1秒前
七月流火的应助被科研通管家采纳,获得100
1秒前
orixero的应助被科研通管家采纳,获得10
1秒前
领导范儿的应助被科研通管家采纳,获得10
2秒前
2秒前
2秒前
2秒前
2秒前
英俊的铭的应助被科研通管家采纳,获得10
2秒前
桐桐的应助被科研通管家采纳,获得10
2秒前
香蕉觅云的应助被科研通管家采纳,获得10
2秒前
Hello的应助被科研通管家采纳,获得10
2秒前
天天快乐的应助被科研通管家采纳,获得10
3秒前
3秒前
打打的应助被科研通管家采纳,获得10
3秒前
FashionBoy的应助被科研通管家采纳,获得10
3秒前
orixero的应助被科研通管家采纳,获得10
3秒前
李爱国的应助被吗瑞采纳,获得10
3秒前
Lucas的应助被Sulunatic采纳,获得10
3秒前
maxiaole的应助被科研通管家采纳,获得20
3秒前
七月流火的应助被科研通管家采纳,获得100
3秒前
小马甲的应助被吗瑞采纳,获得10
3秒前
张天师的应助被科研通管家采纳,获得10
3秒前
李爱国的应助被吗瑞采纳,获得10
4秒前
SciGPT的应助被科研通管家采纳,获得10
4秒前
上官若男的应助被科研通管家采纳,获得10
4秒前
香蕉觅云的应助被吗瑞采纳,获得10
4秒前
所所的应助被科研通管家采纳,获得10
4秒前
张天师的应助被科研通管家采纳,获得10
4秒前
田様的应助被科研通管家采纳,获得10
4秒前
5秒前
5秒前
orixero的应助被u雨采纳,获得10
6秒前
Yewrlon完成签到,获得积分10
6秒前
sxp1031完成签到,获得积分10
6秒前
www发布了新的文献求助10
8秒前
www发布了新的文献求助10
8秒前
10秒前
Leanne完成签到,获得积分10
10秒前
高分求助中
(应助此贴封号)通过应助OA文献获取积分 10000
Composite Materials Handbook Volume 1 - Revision H 1500
Rosenblum, Global Change Biology 800
Computational Chemical Reaction Engineering: Modeling, Simulation, and Design with MATLAB 600
Organizational Behavior 510
Management and the Arts 510
Decentring Leadership 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 计算机科学 工程类 纳米技术 内科学 物理 有机化学 化学工程 生物化学 复合材料 光电子学 细胞生物学 心理学 量子力学 催化作用 物理化学 电极
热门帖子
关注 科研通微信公众号,转发送积分 7807875
求助须知:如何正确求助?哪些是违规求助? 9340452
关于积分的说明 20501769
捐赠科研通 7400081
什么是DOI,文献DOI怎么找? 3328507
关于科研通互助平台的介绍 2475397
邀请新用户注册赠送积分活动 2346859